The molecular mechanisms underlying oncogenesis in leukemias associated with rearrangement of the Mixed Lineage Leukemia (MLL) gene have received a considerable amount of attention over the last two decades. In this review we will focus on recent studies, published over the past year, that reveal new insights into the multi-protein complexes formed by MLL and MLL fusion proteins, the role of epigenetic deregulation in MLL fusion function, downstream transcriptional target genes, the importance of the leukemia cell of origin, the role played by microRNAs, cooperating mutations and the implications that recent research has for the therapy of MLL-rearranged leukemia.
INTRODUCTION
The mixed lineage leukemia (MLL) gene 1,2 on chromosome 11q23 is the frequent target of chromosomal translocations and rearrangements in childhood leukemia and adult therapy-related leukemia. Balanced translocations result in the fusion of the MLL gene to a number of different partner genes, leading to the production of novel chimeric proteins. The homology of the mammalian MLL gene to Drosophila Trithorax, together with experiments in mouse models and human cell lines, suggested that the MLL protein functioned in chromatin modification during development. [3] [4] [5] However, this did not appear to address the role of MLL in leukemia, because one of its major chromatin-modifying domains, the SET histone H3 lysine 4 (H3K4) methyltransferase domain, is excluded from MLL fusion proteins. 6, 7 This problem has been resolved recently by elegant studies from several different laboratories, demonstrating that MLL fusion proteins interfere with transcriptional elongation to deregulate expression of target genes. [8] [9] [10] [11] A number of detailed reviews have already covered these exciting developments and their impact on potential therapeutic approaches to MLL-rearranged leukemia. [12] [13] [14] In this review, we aim to focus on new research that has been published over the past year.
THE MLL COMPLEX
The wild-type MLL protein and MLL fusions bind chromatin by virtue of interactions among menin, the product of the multiple endocrine neoplasia 1 (MEN1) gene, the lens epithelium-derived growth factor (LEDGF/p75) and N-terminal MLL amino acids. [15] [16] [17] Binding of both proteins is essential for MLL fusion-induced leukemia. [17] [18] [19] Two recent studies have further investigated the functional consequences of these interactions. Huang et al. 20 determined the crystal structure of menin, in its free form and in complex with the menin-binding domain of MLL. These revealed that the latter plugs into a deep pocket within menin. Interestingly, although menin binding to MLL causes transcriptional activation of MLL target genes, interaction of menin with the transcription factor JUND has the opposite effect, blocking c-Jun N-terminal kinase-mediated phosphorylation and consequent transcriptional activation of JUND. The crystal structure of menin bound to an N-terminal MLL fragment, containing both the menin-and LEDGF-binding domains, indicated that a surface formed by the interaction between menin and MLL, and distinct to the menin pocket, was responsible for LEDGF binding. Mereau et al. 21 dissected the interaction between MLL and LEDGF to demonstrate that a LEDGF peptide fragment, encompassing the MLL menin-binding domain, was able to compete with LEDGF for binding to MLL. This peptide inhibited growth, colony formation and MLL target gene expression in both mouse and human MLL fusion expressing leukemia cells, but had no such effect in normal mouse hematopoietic progenitor cells and non-MLL-rearranged human leukemia cells. Similar effects were also demonstrated using a much smaller 12 amino-acid LEDGF peptide fragment, derived from a region within the MLL menin-binding domain. Interestingly, expression of either peptide fragment significantly prolonged the latency of MLL-AF9-induced leukemia. The information provided by both these studies will be invaluable in developing small-molecule inhibitors of the interactions between these three proteins.
EPIGENETIC DEREGULATION
The therapeutic potential of targeting epigenetic regulators and chromatin modifiers in MLL-rearranged leukemia was shown in a number of studies demonstrating the importance of different components of the MLL fusion-associated complexes involved in deregulation of transcriptional elongation. Thus, the bromodomain-containing proteins BRD3 and BRD4, 22, 23 the H3K79-specific methyltransferase DOT1L [24] [25] [26] [27] [28] [29] and the polycomb-repressive complex 1 component CBX8 [30] [31] [32] have all been found to be essential for progression of MLL-rearranged leukemia. The importance of DOT1L-mediated H3K79 methylation for transformation by MLL fusion genes was recently extended to MLL-AF10 and MLL-AF6, Chen et al. 33 and Deshpande et al.
and leukemogenesis by these fusion genes. Other recent studies have examined the requirements for lysine-specific demethylase 1a (KDM1A) and PRC2 function in MLL-rearranged leukemia. Harris et al. 35 demonstrated that inhibition of Kdm1a expression impaired MLL-AF9 leukemia colony formation, acute myeloid leukemia (AML) progression in vivo and altered the patterns of histone methylation at MLL-AF9-bound loci. Kdm1a silencing had no effect on normal myeloid progenitor colony formation, although it did inhibit erythroid progenitor development to some extent. Interestingly, loss of KDM1A resulted in reduced expression of genes associated with the MLL-rearranged leukemia stem cell potential and an increase of dimethyl-H3K4 marks, relative to trimethyl-H3K4, at loci bound by MLL-AF9. This suggests that KDM1A is a component of the aberrant MLL fusion-associated transcriptional elongation complex, demethylating dimethyl-H3K4, and thereby ensuring high levels of active trimethyl-H3K4 modifications at the promoters of genes deregulated by MLL fusion proteins.
PRC2 is a complex that mediates transcriptional repression at target loci and is composed of non-catalytic subunits, EED and SUZ12, as well as one of the SET domain methyltransferases, EZH1 or EZH2. 36 Neff et al. 37 examined the requirement for EZH2 and EED in MLL-AF9-induced leukemia. They found that genetic inactivation of Ezh2 in mouse MLL-AF9 leukemia cells impaired but did not block leukemia progression and resulted in reduced H3K27me 3 at the PRC2 target locus Cdkn2a. Tanaka et al.
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reported similar consequences of inactivating the Ezh2 gene. Because EZH2 loss does not completely compromise PRC2 function, potentially being compensated for by EZH1 function, Neff et al. 37 then examined the consequences of Eed inactivation. This resulted in a more profound inhibition of leukemia progression, loss of H3K27me 3 at the Cdkn2a locus and derepression of the tumor suppressors, p16
Ink4a and p19 Arf . Shi et al. 39 used short hairpin RNA-mediated silencing of PRC2 components to confirm these data. Thus, silencing of both Ezh1 and Ezh2, but not either on their own, inhibited proliferation of MLL-AF9 leukemia cells. Silencing Eed or Suz12 was more effective at blocking proliferation and impaired leukemia progression in vivo, and this was largely due to loss of H3K27me 3 at the Cdkn2a locus. Taken together, these studies suggest that therapeutic strategies targeting epigenetic regulation of leukemia-associated gene expression are very promising and rapidly evolving avenue of research in MLL-rearranged leukemia.
TARGET GENES Significant advances in our understanding of the oncogenic mechanisms operating in MLL-rearranged leukemia have come from research investigating aberrant transcriptional control by MLL fusions, the identity of transcriptional target genes and the consequences of their deregulated expression. 12, 40 In WalfVorderwü lbecke et al., 41 we recently established that MLL fusion proteins induce expression of the frequently rearranged, advanced T-cell lymphomas genes (Frat1 and Frat2). The latter was found to be critical for MLL fusion oncogenicity. Consistent with its reported function in non-canonical Wnt signaling, 42 FRAT2 was found to mediate activation of the small Rho GTPases Rac1 and Rac2 by MLL fusions, through a signaling pathway requiring DVL1 and GSK3. This study provides a mechanistic link between transcriptional deregulation by MLL fusion proteins and the previously demonstrated requirement for Rac activation in MLLrearranged leukemia. 43, 44 Furthermore, because FRAT1 is a potentiator of canonical Wnt signaling, this suggests that MLL fusions promote integrated canonical and non-canonical Wnt signaling by deregulating expression of Frat1 and Frat2, and may explain the paradoxical requirement of both canonical Wnt signaling 45, 46 and GSK3 activity 47 in MLL-rearranged leukemia. In a separate study, we found that expression of the RUVBL2 gene was also dependent on MLL fusion proteins. 48 RUVBL2 encodes an AAA( þ ) ATPase family member that functions as part of multi-protein complexes in numerous cellular processes, including chromatin remodeling, DNA repair, regulation of transcription and ribonucleoprotein assembly. 49 RUVBL2 expression and function was found to be essential for proliferation and survival of MLL-AF9-expressing myeloid leukemia cells, suggesting that it represents a promising therapeutic target for MLL-rearranged AML.
Wilkinson et al. 50 
þ cells. Interestingly, RUNX1 was shown to function as a transcriptional activator in MLL-AF4 þ cells and was found to take part in complex formation with the wild-type C-terminal MLL fragment and the AF4-MLL reciprocal fusion product. This study offers a mechanistic explanation for the previously described function of AF4-MLL in t(4;11) acute lymphoblastic leukemia (ALL), 51 suggesting that MLL-AF4 induces RUNX1 expression, whereas AF4-MLL modulates its transcriptional activity. Further evidence for the function of reciprocal MLL fusion genes came from recent a study by Emerenciano et al., 52 demonstrating that the reciprocal Nebulette (NEBL)-MLL fusion protein had more significant growth-promoting activity than MLL-NEBL.
CELL OF ORIGIN
There has been considerable interest in the deleterious impact of high EVI1 (ecotropic viral integration site-1) expression on AML patient survival and its association with MLL-rearranged AML. 53, 54 More recently, Grö schel et al. 55 demonstrated that EVI1 expression defines a high-risk subset within MLL-rearranged AML, as previously indicated in a smaller patient cohort. 54 Bindels et al.
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examined the causal relationship between MLL-AF9 function and Evi1 expression. They demonstrated that MLL-AF9 is responsible for maintaining Evi1 expression following transformation of Evi1-expressing hematopoietic stem cells (HSCs), but did not induce expression in Evi1 À granulocyte macrophage progenitor (GMP) cells. Furthermore, expression of Evi1 in Evi1 þ MLL-rearranged AML was important for leukemia progression. This study confirmed previous data demonstrating deregulation of Evi1 expression by MLL-ENL in HSC-derived AML. 57 Taken together, these data imply that the leukemogenic consequences of MLL fusion gene expression may depend on the identity of the hematopoietic cell in which MLL rearrangement first occurred. Indeed, Krivtsov et al. 58 recently reported that individual clones derived from transformation of HSC by MLL-AF9 were more efficient at inducing leukemia than those derived from GMP. Moreover, the gene-expression signature of leukemia stem cell derived from HSC was enriched in genes associated with poorprognosis MLL-rearranged AML, including high Evi1 expression, and the resulting leukemias were more resistant to the chemotherapeutic agents cytarabine and doxorubicin than GMPderived leukemias. A further twist to this story comes from Horton et al., 59 who demonstrated that human neonatal hematopoietic progenitor cells were more readily transformed by MLL-AF9 than adult bone marrow-derived cells. The former were able to develop along both the lymphoid and myeloid lineages, and induce lymphoid leukemia in vivo, whereas the latter were restricted to myeloid immortalization and were not leukemogenic. Finally, the gene-expression signatures from neonatal MLL-AF9 cells were enriched for genes associated with poor-prognosis pediatric AML and doxorubicin resistance. These studies highlight the critical importance of the cell of origin in determining the potential outcome of MLL-rearranged leukemia and the clinical heterogeneity of this disease.
MICRORNAS
The function of microRNAs in the development and classification of leukemia has received considerable attention. [60] [61] [62] Four recent publications have concentrated on microRNA function in MLLrearranged leukemia. Li et al. 63 studied the role of miR-196b in MLL-rearranged AML. Induction of miR-196b expression by MLL fusions was previously shown to be required for immortalization. 64 Interestingly, Li et al. 63 demonstrated that further overexpression of miR-196b delayed AML induction by MLL fusions in primary recipients, but accelerated it in secondary transplantations. The pro-and anti-leukemogenic effects of this miR may be explained by its simultaneous repression of oncogenic (Hoxa9 and Meis1) and tumor-suppressor (Fas) gene expression. Nishi et al. 65 reported that MLL fusions cause suppression of let-7b expression, a miR exhibiting reduced expression in MLL-rearranged ALL. 62 This suppression is ensured by hypermethylation of let-7b-regulatory regions, and overexpression of let-7b inhibits growth of MLLrearranged ALL. Jiang et al. 66, 67 recently demonstrated that MLL fusions also repress miR expression in AML. Thus, expression of miR-150 was found to be reduced in most AML, 67 and MLL fusions were found to repress miR-150 by induction of MYC gene expression, leading to the consequent upregulation of LIN28, an RNA-binding protein that blocks miR-150 maturation. Overexpression of miR-150 inhibited growth and impaired leukemia progression of MLL-rearranged AML, possibly by repressing FLT3 and MYB expression. In contrast to the expression pattern of miR-150 in AML, expression of miR-495 was found to be specifically reduced in MLL-rearranged AML. 66 Overexpression of miR-495 was also found to inhibit MLL fusion leukemogenesis, this time by repression of MEIS1 and PBX3 expression. Taken together, these studies illustrate the complex roles of miR in MLL-rearranged leukemia and the therapeutic potential of interfering with the control of their expression.
COOPERATING MUTATIONS
Several recent studies have highlighted the potential importance of cooperating mutations in MLL-rearranged leukemia progression. Bergerson et al. 68 used a murine leukemia virus insertional mutagenesis screen to identify Mn1, Bcl11a and Fosb as putative cooperating genes in MLL-AF9-induced leukemia. Takacova et al. 69 generated a regulatable MLL-ENL knock-in mouse, expressing a deletion variant of MLL-ENL 70 in a tamoxifen-dependent manner. Expression of this variant MLL-ENL allele induced myeloproliferation and subsequent myeloid senescence. The transition between myeloproliferation and senescence result coincided with the induction of DNA-damage responses and was promoted by inflammatory mediators. Inhibition of DNA repair with caffeine accelerated the disease and resulted in progression to overt leukemia, suggesting that this signaling pathway represents a potential target for cooperating mutations. Jenkins et al. 71 examined the role of insulin-like growth factor 1 receptor (IGF1R) signaling in MLL-rearranged leukemia. They found that reduction of IGF1R expression in GMP, but not HSC, decreased the susceptibility to leukemia induction by MLL-AF9. However, genetic inactivation of IGF1R in cells that had become leukemic had no effect, suggesting that IGF1R signaling cooperates with MLL fusions in myeloid transformation but is not required for maintenance of leukemia. Finally, Zorko et al. 72 examined leukemogenic cooperation between the MLL partial tandem duplication and FLT3 internal tandem duplication mutations. Although neither Mll partial tandem duplication nor FLT3 internal tandem duplication knock-in mice develop leukemia, crossing the two resulted in a double knock-in mouse model that developed AML with 100% penetrance. These studies identify novel targets for potential therapeutic targeting and describe experimental models that will be useful for developing therapeutic agents.
THERAPEUTIC IMPLICATIONS
Recent studies have provided a number of exciting examples of novel therapeutic approaches to treat MLL-rearranged leukemia. Some reports suggest that the efficacy of conventional chemotherapy may be increased by inhibition of the transcriptional and signaling pathways operating in MLL-rearranged leukemia. For example, Walf-Vorderwü lbecke et al. 41 show that this can be achieved by suppressing non-canonical Wnt signaling, Fratdeficient MLL-ENL cells exhibiting increased doxorubicin sensitivity. Likewise, Bindels et al. 56 demonstrate increased sensitivity of Evi1 þ MLL-AF9 AML cells to cytarabine and idarubicin following Evi1 silencing. Spijkers-Hagelstein et al. 73 found that prednisolone sensitivity of MLL-AF4 þ ALL cells was related to Ca 2 þ release induced by the drug, and that inhibition of the S100A8/S100A9 calcium-binding proteins by the Src kinase inhibitor PP2 sensitized resistant MLL-AF4 þ ALL cells toward prednisolone. In a separate study, Spijkers-Hagelstein et al. 74 showed that prednisolone sensitization of resistant MLLrearranged ALL cells by Src inhibition was also due to loss of Src-induced annexin A2 phosphorylation. Accordi et al. 75 demonstrated that pharmacological inhibition of the AMPactivated protein kinase (AMPK), activation of which is associated with MLL-rearranged B-progenitor ALL, selectively induced apoptosis in MLL-rearranged ALL cell lines and primary patient cells. Furthermore, AMPK inhibition sensitized the leukemia cells to the anti-proliferative activities of a number of standard chemotherapeutic drugs.
There have also been several reports describing the development of novel small-molecule inhibitors, targeting the MLL complex and associated epigenetic regulators. Grembecka et al. 76 used high-throughput screening to identify the smallmolecule inhibitors, MI-2 and MI-3, that interfered with the interaction between menin and MLL. As predicted, these inhibitors blocked the binding of MLL-AF9 to the promoters of transcriptional target genes and reduced target gene expression. The inhibitors were effective at blocking hematopoietic transformation by MLL fusion genes and induced growth inhibition, differentiation and apoptosis of both mouse and human MLL-rearranged leukemias. The inhibitors also demonstrated selectivity for leukemia cells harboring MLL fusions. Shi et al. 77 then determined the crystal structure of MI-2 bound to menin, and used it to develop a second-generation inhibitor MI-2 that exhibited increased potency against MLLrearranged leukemia cells.
The efficacy of targeting MLL-associated epigenetic regulators has been established by the identification of small-molecule inhibitors capable of blocking BRD3/4 23 and DOT1L 78 activity. Yu et al. 79 have recently solved the structure of DOT1L bound to its small-molecule inhibitor, EPZ004777, 78 to develop the chemical analogue SGC0946 that exhibits improved solubility and increased potency of H3K79-methylation inhibition in MLL-rearranged leukemia cells. Harris et al. 35 demonstrated that KDM1A inhibition by two derivative compounds of tranylcypromine was effective at inhibiting colony formation by MLL-rearranged cell lines and primary human MLL-AF9 þ leukemia cells. Moreover, the inhibitors showed a high degree of selectivity for MLL-rearranged leukemia cells.
Harnessing the unforeseen potential of existing drugs by redeployment or repurposing into clinical use distinct to their original indications is currently receiving considerable attention. 80 Connectivity mapping is one approach to identify suitable candidates for redeployment and is based on the comparison of oncogene-associated gene-expression profiles with those induced by drugs. 81 Stumpel et al. 82 used connectivity mapping to identify histone deacetylase inhibitors as candidate drugs with potential to reverse the hypomethylation-based gene signature associated with MLL-AF4 þ ALL. The histone deacetylase inhibitors were shown to target MLL-AF4 þ ALL cells, increasing promoter methylation and inhibiting expression of a number of protooncogenes. Interestingly, one of the compounds inhibited MLL-AF4 expression as well.
CONCLUSIONS
In conclusion, this brief review of recent publications on MLLrearranged leukemia illustrates how rapidly this field of research is expanding and the full translational potential of harnessing the mechanistic insights into these diseases for future clinical benefit. The first examples of new drugs and novel applications are now beginning to emerge that may revolutionize the treatment options for patients with this form of leukemia.
